JP5725605B2 - 軽度認知障害を処置するためのフェノチアジン化合物 - Google Patents

軽度認知障害を処置するためのフェノチアジン化合物 Download PDF

Info

Publication number
JP5725605B2
JP5725605B2 JP2010512761A JP2010512761A JP5725605B2 JP 5725605 B2 JP5725605 B2 JP 5725605B2 JP 2010512761 A JP2010512761 A JP 2010512761A JP 2010512761 A JP2010512761 A JP 2010512761A JP 5725605 B2 JP5725605 B2 JP 5725605B2
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
carboaryl
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010512761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530403A (ja
JP2010530403A5 (enExample
Inventor
ヴィスシック，クロード・ミシェル
ハーバラン，ドミニク・ヴェネイ
リーデル，ゲルノート
ディアーナ，セレーナ
ゴートマン，エリザベス・アン
ウィズシック，デイモン・ジュード
マレー，アリソン・ドロシー
スタッフ，ロジャー・トッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of JP2010530403A publication Critical patent/JP2010530403A/ja
Publication of JP2010530403A5 publication Critical patent/JP2010530403A5/ja
Application granted granted Critical
Publication of JP5725605B2 publication Critical patent/JP5725605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010512761A 2007-06-19 2008-06-17 軽度認知障害を処置するためのフェノチアジン化合物 Active JP5725605B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
US60/945,006 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (3)

Publication Number Publication Date
JP2010530403A JP2010530403A (ja) 2010-09-09
JP2010530403A5 JP2010530403A5 (enExample) 2011-08-04
JP5725605B2 true JP5725605B2 (ja) 2015-05-27

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512761A Active JP5725605B2 (ja) 2007-06-19 2008-06-17 軽度認知障害を処置するためのフェノチアジン化合物

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007008550D1 (de) 2006-03-29 2010-09-30 Wista Lab Ltd 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
US9149481B2 (en) * 2007-10-03 2015-10-06 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
CN102958525B (zh) 2010-04-30 2017-05-24 普罗瑟塔抗病毒股份有限公司 抗病毒化合物
AU2011358840B2 (en) * 2011-02-11 2017-05-04 TauRx Therapeutics Management Ltd Phenothiazine diaminium salts and their use
WO2012145567A1 (en) 2011-04-20 2012-10-26 Prosetta Antiviral Inc. Antiviral compounds
WO2014120907A1 (en) * 2013-01-30 2014-08-07 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
WO2016133995A1 (en) 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
HRP20230628T1 (hr) * 2016-07-25 2023-09-29 Wista Laboratories Ltd. Primjena i doziranje diaminofenotiazina
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
PT3826639T (pt) 2018-07-26 2024-10-09 Wista Lab Ltd Dosagem otimizada de diaminofenotiazinas em populações
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
JP2025518248A (ja) 2022-05-31 2025-06-12 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム（ｍｔ）含有化合物を利用した神経変性障害の処置
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
CN1791408A (zh) * 2003-04-03 2006-06-21 普拉纳生物技术有限公司 神经系统疾病的治疗
US7790881B2 (en) * 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
EP1799662B1 (en) * 2004-09-23 2013-04-17 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
EP2853293B1 (en) * 2006-03-29 2017-11-22 WisTa Laboratories Ltd. Thioninium compounds and their use
DE602007008550D1 (de) 2006-03-29 2010-09-30 Wista Lab Ltd 3,7-diamino-10h-phenothiazinsalze und ihre verwendung
JP5654748B2 (ja) * 2006-03-29 2015-01-14 ウイスタ・ラボラトリーズ・リミテッドＷｉｓｔａ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｔｄ． タンパク質凝集の阻害物質
EP2457904B1 (en) * 2006-07-11 2014-11-19 Wista Laboratories Ltd. Methods of synthesis and/or purification of diaminophenothiazinium compounds

Also Published As

Publication number Publication date
WO2008155533A2 (en) 2008-12-24
AU2008265045B2 (en) 2014-02-27
PL2167095T3 (pl) 2019-11-29
JP2010530403A (ja) 2010-09-09
DK2167095T3 (da) 2019-07-29
AU2008265045A1 (en) 2008-12-24
PT2167095T (pt) 2019-08-06
US9211294B2 (en) 2015-12-15
US20100184752A1 (en) 2010-07-22
CN101820884A (zh) 2010-09-01
CA2690746A1 (en) 2008-12-24
EP2167095B1 (en) 2019-05-29
SI2167095T1 (sl) 2019-09-30
CN101820884B (zh) 2013-08-28
HUE045460T2 (hu) 2019-12-30
MY177001A (en) 2020-09-01
EP2167095A2 (en) 2010-03-31
CA2690746C (en) 2018-01-02
BRPI0813670A2 (pt) 2014-12-30
ES2739546T3 (es) 2020-01-31
WO2008155533A3 (en) 2009-02-19
HRP20191513T1 (hr) 2019-11-29

Similar Documents

Publication Publication Date Title
JP5725605B2 (ja) 軽度認知障害を処置するためのフェノチアジン化合物
ES2327521T3 (es) Procedimientos de prevencion, tratamiento y diagnostico de trastornos de la agregacion de proteinas.
US20200338040A1 (en) Methods for treating alzheimer's disease and related disorders
WO2014025905A1 (en) Multi-component formulation for improving neurological function
TW202019471A (zh) 阿茲海默症之治療及預防方法
JP2012525341A (ja) 一次進行型多発性硬化症の治療のためのキノン誘導体２，３−ジメトキシ−５−メチル−６−（１０−ヒドロキシデシル）−１，４−ベンゾキノン
JP2022092013A (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
Moretti et al. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia
CN120826221A (zh) 鲨肌醇和维生素d和/或其他维生素或活性成分的组合治疗用以治疗认知障碍
CA3214354A1 (en) Treatment of prodromal huntington disease
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
US20230031369A1 (en) Therapeutic interactions of leucomethylthioninium
US20240050427A1 (en) Treatments for obsessive compulsive disorder
JP7333942B2 (ja) 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法
RU2834773C2 (ru) Терапевтические взаимодействия лейкометилтиониния
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
Grossman Dementia overview
WO2024238524A1 (en) Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
BR122025003268A2 (pt) Métodos de tratamento e prevenção de doença de alzheimer
Durumlar Post-stroke Neuropsychiatric Problems

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130730

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141002

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150327

R150 Certificate of patent or registration of utility model

Ref document number: 5725605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250